This project will advance the understanding of the molecular basis of Acute Myeloid Leukemia (AML), one of the most aggressive blood cancers. The project will establish a national registry of Israeli AML patients, including clinical data as well as genetic and molecular characteristics, and the drug responsiveness of patient-derived AML cells. The resulting unique integrated database will be available to attending physicians for the purpose of optimizing AML treatment in a personalized manner.